Mismatch-repair deficient (MSI-high) colorectal cancer

What changed: Mismatch-repair deficient (MSI-high) colorectal cancer

Cancer page →

Every dated change on the records linked to Mismatch-repair deficient (MSI-high) colorectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Regulatory1Trial result5Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMismatch-repair deficient (MSI-high) colorectal cancer
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026Trial resultAZUR-1
AZUR-1 reported
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.

April 2025 · 1

2025-04RegulatoryIpilimumab
Ipilimumab: approval (US)
With nivolumab first-line MSI-H/dMMR colorectal cancer (CheckMate 8HW)

2025 · 2

2024 · 2

2022 · 2

2020 · 2

2017 · 1

2017MilestonePembrolizumab
FDA approves pembrolizumab for any mismatch-repair deficient solid tumour, the first tissue-agnostic approval
A milestone in how this cancer is treated.

2015 · 1

2015MilestonePembrolizumab
Le and Diaz: PD-1 blockade works in mismatch-repair deficient tumours (NEJM)
A milestone in how this cancer is treated.

1993 · 1

1993MilestoneMicrosatellite instability (MSI-H) / mismatch repair deficiency (dMMR)
Microsatellite instability discovered in colorectal cancer and linked to hereditary non-polyposis colorectal cancer
A milestone in how this cancer is treated.